RESUMO
OBJECTIVES: The objective of this study was to correlate maximum standardized uptake value (SUVmax) with different immunohistochemical subtypes of breast cancer and other prognostic factors in breast cancer. SUBJECTS AND METHODS: This was a retrospective study including 219 consecutive patients undergoing whole-body fluorodeoxyglucose positron emission tomography/computed tomography scan for the staging of breast cancer. Out of 219 patients, two were male and 217 were female; age ranged from 26 to 85 years with mean age of 54 years. On histopathological examination (HPE), 197 patients were of invasive ductal carcinoma type and two of lobular type. Histopathological grades, immunohistochemistry (IHC) types, and ki-67 values were compared with SUVmax values. RESULTS: The mean SUVmax of the population was 11.39 (±6.05). The mean SUVmax in different HPE grades was Grade 1 = 6.81 ± 5.6, Grade 2 = 11.4 ± 6.12, and Grade 3 = 13.14 ± 5. The mean SUVmax values in different IHC types were Luminal A = 7.75 ± 4.2, Luminal B = 10.01 ± 5.3, triple negative = 15.26 ± 5.6, and HER2 enriched = 11.27 ± 5.2. The mean SUVmax in high ki-67 patients was 11.97 ± 5.85 compared with 7.25 ± 3.43 patients with low ki-67. Univariate analysis showed significant difference in SUVmax in patients with different grades (P = 0.013), hormone receptor positivity (P ≤ 0.001), ki-67 (P < 0.001), and axillary lymph node positivity (P ≤ 0.001). In multivariate regression analysis, there was significantly higher SUVmax value in triple-negative patients after correcting for tumor size, ki-67 value, axillary lymph node status, and grade of tumor. CONCLUSION: High SUVmax values were noted in high-grade, high ki-67, triple-negative, and axillary lymph node positive tumors.
RESUMO
Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a rare and poorly differentiated type of cutaneous T-cell lymphoma. In this variant, the lymphoma cells infiltrate preferentially into the subcutaneous adipose tissue. It is an indolent type of non-Hodgkin's lymphoma and can be mistaken for panniculitis. Here, we describe the case of a 59-year-old female patient who presented with altered skin pigmentation with diffuse plaque-like patches in the skin around the thighs and legs. A skin biopsy revealed subcutaneous lobular panniculitis composed of lymphocytes, epithelioid histiocytes, and occasional giant cells admixed with atypical lymphoid cells, which were suggestive of cutaneous lymphoma. Immunohistochemistry showed CD3 positive, CD20 negative, CD8 positive, CD4 occasional cells positive, CD56 negative, and CD5 few cells positive, confirming the diagnosis of SPTCL. Therefore, cases with atypical and nonresolving dermatological lesions should raise a suspicion of SPTCL as diagnosis against other benign conditions.
RESUMO
Castleman's disease (CD) is a rare benign lymphoproliferative disorder. We are presenting three cases of CD of which one is unicentric CD, and the other two are an idiopathic multicentric CD. One of the two multicentric cases is associated with POEMS syndrome. The whole body 18F-Fluorodeoxyglucose positron-emission tomography-computed tomography scan plays a significant role in identifying the centricity, distribution of disease, response to therapy, and in early detection of remission.
RESUMO
AIM: In newly diagnosed carcinoma breast cancer patients, comparing conventional staging and 18F-fluorodeoxyglucose positron-emission tomography-computed tomography (18F-FDG PET/CT) staging. MATERIALS AND METHODS: This was a retrospective observational study. A total of 171 new diagnosed carcinoma breast patients who underwent staging 18F-FDG PET/CT scan and routine conventional imaging including mammosonography of breast and axilla, chest X-ray, ultrasound sonography abdomen, and bone scan were included in the study. Staging was done according to the American Joint Committee on Cancer staging (tumor-node-metastasis). Changes in staging and management with 18F-FDG PET/CT scan were assessed. RESULTS: Overall PET/CT upstaged in 22.2% of cases and changed management in 15.78% of cases. PET/CT upstaged in three of eight cases in Stage IA patients but changed management in only one case. In Stage IIA, of 31 patients PET/CT upstaged in two patients (6.45%). In Stage IIB, of 45 patients PET/CT upstaged in six patients (13.3%). In Stage IIIA, of 22 patients PET/CT upstaged in six patients (27.2) and in five patients there is a change in management. In Stage IIIB, of 43 patients PET/CT upstaged in 21 patients (48.8%) with change in management in 13 patients (25.5%). CONCLUSION: 18F-FDG PET/CT scan can be helpful in a significant number of patients with Stage IIB and above in upstaging and changing management.
RESUMO
Fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET-CT) is a useful proven imaging modality in the management of many types of cancers. It is being used at various stages of treatment of cancer. Knowledge regarding the physiological biodistribution and false-positive findings should be kept in mind for correct interpretation. Pulmonary FDG uptake can be due to different causes such as infection, inflammation, and metastases which are invariably associated with structural abnormality on CT. In rare circumstances, there can be a focus of FDG uptake in the lung with no corresponding structural abnormality which might be due to an inflammatory vascular microthrombus or due to iatrogenic microembolism caused during the injection of radiotracer. It is important to be aware of this as it can cause difficulty in interpreting the scan and can lead to false-positive findings. It also highlights the importance of hybrid imaging in the form of PET-CT as there is a definite possibility of misinterpreting this as a site of metastasis in a known carcinoma patient if there was no corresponding CT image.
